On December 20, 2024, Eli Lilly announced the FDA has approved Zepbound (tirzepatide) as the first and only prescription medication for adults with moderate-to-severe obstructive sleep apnea and obesity. AASM.org Among persons with moderate-to-severe obstructive sleep apnea and obesity, tirzepatide reduced the AHI, body weight, hypoxic burden, hsCRP concentration, and systolic blood pressure and improved sleep-related patient-reported outcomes. NIH study Can the makers of these new weight loss medications really claim to treat and cure Obstructive Sleep Apnea (OSA)
Most best glutathione injection products have a shelf life of 1-2 years when stored properly
offers powders, research chemicals or compounded products instead of authorised medicines
It plays a particularly strong role in the gut, acting throughout the digestive tract to aid digestion
The medication's effects on bowel movements vary considerably among individuals, with some experiencing increased frequency and others decreased frequency